USMLE Step 1 practice question: Cryptococcal meningitis: flucytosine mechanism (conversion to 5-fluorouracil)

USMLE Step 1MicrobiologyPharmacology

A 38-year-old man with HIV infection comes to the emergency department because of a 2-week history of worsening headache, fever, and nausea. His partner reports that he has been increasingly forgetful over the past 3 days. He stopped taking antiretroviral therapy 3 years ago. His temperature is 38.3°C (100.9°F), pulse is 98/min, and blood pressure is 124/78 mm Hg. He is oriented to person only. Neck flexion causes mild discomfort. Funduscopic examination shows bilateral papilledema. There are no focal neurologic deficits. His CD4+ T-lymphocyte count is 38/mm³. A CT scan of the head shows no abnormalities. Lumbar puncture shows an opening pressure of 34 cm H₂O (N = 10–20). Cerebrospinal fluid analysis shows: Leukocyte count 24/mm³ (90% lymphocytes) Protein 74 mg/dL Glucose 32 mg/dL An India ink preparation shows round budding yeasts surrounded by wide clear halos. He is started on the preferred induction regimen, consisting of liposomal amphotericin B and a second, orally administered antifungal agent.

Which of the following is the mechanism of action of the second drug?

  1. Binding to ergosterol, forming pores in the fungal cell membrane
  2. Inhibition of β-(1,3)-D-glucan synthesis in the fungal cell wall
  3. Inhibition of lanosterol 14α-demethylase in ergosterol synthesis
  4. Inhibition of squalene epoxidase in ergosterol synthesis
  5. Intracellular conversion to 5-fluorouracil, which inhibits nucleic acid synthesis
Show answer and explanation

Correct answer: E. Intracellular conversion to 5-fluorouracil, which inhibits nucleic acid synthesis

This patient with advanced HIV infection (CD4+ count <100/mm³) has cryptococcal meningitis, caused by the encapsulated yeast Cryptococcus neoformans, which is acquired by inhalation (eg, from soil contaminated with pigeon droppings) and disseminates hematogenously to the meninges. Typical features are a subacute headache, fever, and altered mentation with only mild meningismus; a markedly elevated opening pressure (often >25 cm H₂O) with papilledema; and CSF showing mild lymphocytic pleocytosis, elevated protein, and low glucose. India ink staining shows yeasts with a thick polysaccharide capsule (clear halo), and cryptococcal antigen testing of CSF or serum is the most sensitive rapid test.

The preferred induction therapy is liposomal amphotericin B plus flucytosine for at least 2 weeks, followed by consolidation and maintenance therapy with fluconazole. Flucytosine (5-fluorocytosine) is taken up by fungal cells via cytosine permease and is deaminated by fungal cytosine deaminase to 5-fluorouracil (5-FU). 5-FU is converted to 5-fluorodeoxyuridine monophosphate, which inhibits thymidylate synthase (blocking DNA synthesis), and to 5-fluorouridine triphosphate, which is incorporated into RNA and disrupts protein synthesis. Human cells lack cytosine deaminase, which confers selectivity, although intestinal bacteria can convert flucytosine to 5-FU and contribute to toxicity. Because resistance emerges rapidly with monotherapy, flucytosine is always combined with amphotericin B, with which it is synergistic (amphotericin-induced membrane pores enhance flucytosine entry). The main adverse effects are dose-related bone marrow suppression (leukopenia, thrombocytopenia), hepatotoxicity, and GI upset; because flucytosine is renally cleared, amphotericin-induced nephrotoxicity can raise its levels. Additional management includes serial therapeutic lumbar punctures to control intracranial pressure and delaying antiretroviral therapy for 4–6 weeks to reduce the risk of immune reconstitution inflammatory syndrome.

High-yield summary: Cryptococcal meningitis (CD4+ <100/mm³, India ink halo, CSF antigen, high opening pressure) → induction with amphotericin B + flucytosine, then fluconazole. Flucytosine → 5-FU via fungal cytosine deaminase → inhibition of thymidylate synthase and RNA function; toxicity = myelosuppression.

Why the other options are wrong

  • A. Binding to ergosterol, forming pores in the fungal cell membrane — Binding to ergosterol and forming membrane pores is the mechanism of amphotericin B (and nystatin), the first drug in this regimen; amphotericin B is given intravenously, not orally.
  • B. Inhibition of β-(1,3)-D-glucan synthesis in the fungal cell wall — Echinocandins (caspofungin, micafungin, anidulafungin) inhibit β-(1,3)-D-glucan synthase, but they have no meaningful activity against Cryptococcus and are not used for cryptococcal infections.
  • C. Inhibition of lanosterol 14α-demethylase in ergosterol synthesis — Azoles (eg, fluconazole) inhibit lanosterol 14α-demethylase (CYP51); fluconazole is used for consolidation and maintenance therapy, but the preferred partner for amphotericin B during induction is flucytosine.
  • D. Inhibition of squalene epoxidase in ergosterol synthesis — Terbinafine inhibits squalene epoxidase and is used for dermatophyte infections such as onychomycosis; it has no role in the treatment of cryptococcal meningitis.

Key point

Induction therapy for cryptococcal meningitis is amphotericin B plus flucytosine, which is converted by fungal cytosine deaminase to 5-fluorouracil and inhibits fungal DNA and RNA synthesis.

Memory hook

Crypto combo ‘Ampho + 5-FC’: fungi turn flucytosine into 5-FU and poison their own DNA; humans lack cytosine deaminase—but marrow still suffers.

Share: Telegram WhatsApp X LinkedIn

Practice like this every day

15 free bank questions a day, exam-length timed blocks, spaced repetition and 3D anatomy — in English and Russian.

Play free

More free questions in this system

Acyclovir-resistant HSV: thymidine kinase deficiencyUSMLE Step 1 · MicrobiologyAcute uncomplicated cystitis in a nonpregnant woman: 5-day nitrofurantoinUSMLE Step 2 CK · MicrobiologyChronic aortic regurgitationUSMLE Step 1 · CardiovascularPharmacokinetics: volume of distribution and oral loading doseUSMLE Step 1 · PharmacologyAutosomal recessive recurrence risk (cystic fibrosis, unaffected sibling = 2/3 carrier)USMLE Step 1 · GeneticsCisplatin toxicity (ototoxicity, nephrotoxicity, hypomagnesemia): DNA cross-linkingUSMLE Step 1 · Hematology/Oncology

All free questions →